Expression of Fas in Renal Cell Carcinoma

Japanese Journal of Clinical Oncology

Volumn 27, Issue 6, 1997, Pages 384-388

  Horie, Shigeo ^a,b   Kano, Munehide ^b   Higashihara, Eiji ^c   Moriyama, Nobuo ^b   Tanaka, Etsuko ^b   Hirose, Akiko ^b   Kakizoe, Tadao ^a   Kawabe, Kazuki ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYORIN UNIVERSITY   (Japan)

Author keywords

Anti Fas antibody; Apoptosis; Fas; Renal cell carcinoma

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CELL CULTURE; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031307755     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.6.384     Document Type: Article

References (18)

1. Kerr JFR, Winterford CM, Harmon BY Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
2. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-56.
3. Leithäiser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
4. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Sem Oncol 1983;10:422-30.
5. Finney R. The value of radiotherapy in the treatment of hypernephroma - a clinical trial Br J Urol 1973;45:258-69.
6. Miyao N, Tsukamoto T, Kumamoto Y. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2 and SMKT-R-3) and their characters. Urol Res 1989;17:317-24.
7. Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol 1992;148:1778-81.
8. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
9. Moriyama N, Akaza H, Suzuki T, Kawabe K, Niijima T. Inverted papilloma: observation with scanning and transmission electron microscopy. Virchows Arch [Pathol Anat] 1985;407:25-32.
10. Tsukamoto T, Kumamoto Y, Takahashi A, Yanase M, Yamazaki K, Miyao N, et al. Tumor size of renal cell carcinoma, its clinical implication. Urol Int 1992;48:378-83.
11. Targonski PV, Frank W, Stuhldreher D, Guinan PD. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients. J Urol 1994;152:1389-92.
12. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells, induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-64.
13. Törmänen U, Eerola AK, Rainio P, Vähäkangas K, Soini Y, Sormunen R, Bloigu R, et al Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595-602.
14. Vesalainen S, Lipponen P, Talja M, Syrjänen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-1803
15. Lipponen PK, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-73.
16. Lipponen PK, Aaltomaa S, Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-9.
17. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer Cancer Res 1995;55:1811-16.
18. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: level of Fas and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.